From: Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
Patients Φ
(%)
Deaths
HR
95%CI*
P
Cohort 1
UM
30
(44.1)
14
1.0(ref)
M
38
(55.9)
12
0.53
0.23 to 1.23
0.14
Cohort 2
50
(53.8)
21
43
(46.2)
28
0.50
0.23 to 1.08
0.08